Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.44 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | TK1 | P04183 | 4/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420314 | 0.98 | MAPK1 (0.46) | MAPK1HPGDDAOTYMPCRBN | |
| SCHEMBL8952525 | 0.84 | CRBN (0.43) | MAPK1HPGDDAOTYMPCRBN | |
| SCHEMBL10105028 | 0.77 | KMT2A (0.40) | MAPK1HPGDDAOTYMPALDH1A1 | |
| SCHEMBL9910660 | 0.77 | MAPK1 (0.44) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL20998663 | 0.77 | CRBN (0.39) | MAPK1DAOCRBNALDH1A1 | |
| SCHEMBL10105030 | 0.77 | CRBN (0.39) | MAPK1DAOCRBNTK1 | |
| SCHEMBL19244642 | 0.76 | ALDH1A1 (0.35) | MAPK1HPGDTYMPALDH1A1LMNA | |
| SCHEMBL646139 | 0.76 | TDP1 (0.59) | MAPK1HPGDTYMPCRBNALDH1A1 | |
| SCHEMBL12338478 | 0.76 | DAO (0.40) | MAPK1DAOCRBN | |
| SCHEMBL3584096 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1763 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734976-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RyCarma Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025006617-A2 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| US-20240177800-A1 | ALIGNMENT AND COMPARISON OF GENETIC INFORMATION | GEORGE MASON UNIVERSITY | 2024-05-30 | — | — | US | claimed |
| US-20230027396-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | COMERA LIFE SCIENCES, INC. | 2023-01-26 | — | — | US | claimed |
| EP-4065166-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | Comera Life Sciences, Inc. (US) | 2022-10-05 | — | — | EP | claimed |
| WO-2021108427-A1 | EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS | REFORM BIOLOGICS, LLC (US) | 2021-06-03 | — | — | WO | claimed |
| US-10023863-B2 | Therapeutics with conformationally restricted monomers | MARINA BIOTECH, INC. (US) | 2018-07-17 | — | — | US | claimed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | claimed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | claimed |
| EP-0719267-A4 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS INC (US) | 1996-02-16 | — | — | EP | claimed |
| EP-0623133-A4 | SUBSTITUTED AMINO ALKYL COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1995-10-11 | — | — | EP | claimed |
| WO-1995022546-A1 | INTRACELLULAR SIGNALLING MEDIATORS | CELL THERAPEUTICS, INC. (US) | 1995-08-24 | — | — | WO | claimed |
| WO-1994022863-A9 | SECOND MESSENGER CELL SIGNALING INHIBITORS | — | 1994-12-22 | — | — | WO | claimed |
| EP-0623133-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-11-09 | — | — | EP | claimed |
| WO-1994024133-A1 | RING-SUBSTITUTED CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| WO-1994022449-A1 | THERAPEUTIC COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994022863-A1 | SECOND MESSENGER CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1994-10-13 | — | — | WO | claimed |
| WO-1994015606-A1 | OLEFIN-SUBSTITUTED LONG CHAIN COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1994011370-A1 | SUBSTITUTED AMINO ALKYL COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | MAPK1 1861/4885HPGD 2048/4885DAO 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.